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High plasma levels of fenretinide [N-(4-hydroxyphenyl)retinamide (4-HPR)] were associated with improved outcome in a
phase II clinical trial. Low bioavailability of 4-HPR has been limiting its therapeutic applications. This study characterized
metabolism of 4-HPR in humans and mice, and to explore the effects of ketoconazole, an inhibitor of CYP3A4, as a modulator
to increase 4-HPR plasma levels in mice and to increase the low bioavailability of 4-HPR.
EXPERIMENTAL APPROACH
4-HPR metabolites were identiﬁed by mass spectrometric analysis and levels of 4-HPR and its metabolites
[N-(4-methoxyphenyl)retinamide (4-MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR)] were quantiﬁed by
high-performance liquid chromatography (HPLC). Kinetic analysis of enzyme activities and the effects of enzyme inhibitors
were performed in pooled human and pooled mouse liver microsomes, and in human cytochrome P450 (CYP) 3A4
isoenzyme microsomes. In vivo metabolism of 4-HPR was inhibited in mice.
KEY RESULTS
Six 4-HPR metabolites were identiﬁed in the plasma of patients and mice. 4-HPR was oxidized to 4-oxo-4-HPR, at least in part
via human CYP3A4. The CYP3A4 inhibitor ketoconazole signiﬁcantly reduced 4-oxo-4-HPR formation in both human and
mouse liver microsomes. In two strains of mice, co-administration of ketoconazole with 4-HPR in vivo signiﬁcantly increased
4-HPR plasma concentrations by > twofold over 4-HPR alone and also increased 4-oxo-4-HPR levels.
CONCLUSIONS AND IMPLICATIONS
Mice may serve as an in vivo model of human 4-HPR pharmacokinetics. In vivo data suggest that the co-administration of
ketoconazole at normal clinical doses with 4-HPR may increase systemic exposure to 4-HPR in humans.
Abbreviations
4-EPR, N-(4-ethoxyphenyl)retinamide; 4-HPR (fenretinide), N-(4-hydroxyphenyl)retinamide; 4-MPR,
N-(4-methoxyphenyl)retinamide; 4-oxo-4-HPR, 4-oxo-N-(4-hydroxyphenyl)retinamide; ATRA, all-trans retinoic acid;
CYP, cytochrome P450; HLM, human liver microsomes; LC/MS/MS, liquid chromatography-tandem mass spectrometry;
MLM, mouse liver microsomes; NOD/SCID, non-obese diabetic/severe combined immune deﬁciency; RT-PCR, real-time
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Fenretinide [N-(4-hydroxyphenyl)retinamide; 4-HPR] is a
synthetic analogue of all-trans retinoic acid (ATRA) that
exhibits cytotoxic activity against a variety of human cancer
cell lines in vitro at concentrations of 1–10 mM (Delia et al.,
1993; Mariotti et al., 1994; Kalemkerian et al., 1995; Oridate
et al., 1996; O’Donnell et al., 2002). 4-HPR has also been
studied clinically both as a chemopreventive agent in breast
(Veronesi et al., 1999), bladder (Sabichi et al., 2008) and oral
mucosal cancers (Chiesa et al., 2005), and more recently as a
chemotherapeutic agent in paediatric (Garaventa et al., 2003;
Villablanca et al., 2006) and adult cancers (Puduvalli et al.,
2004; Vaishampayan et al., 2005; Reynolds et al., 2007).
Despite substantial in vitro cytotoxicity, response rates in
clinical trials with 4-HPR have been less than anticipated,
probably due to the low bioavailability of the oral capsule
formulation employed (Cheng et al., 2001; Puduvalli et al.,
2004; Vaishampayan et al., 2005; Reynolds et al., 2007;
William et al., 2009).
After a single 10 mg·kg
-1 dose of the capsules, the oral
bioavailability of 4-HPR was approximately 16% in beagle
dogs (Liu et al., 2007). In chemoprevention studies utilizing
chronic, low-dose schedules (100–400 mg daily), 4-HPR
plasma concentrations were 3 mM (Formelli and Cleris,
1993). A paediatric phase I study in neuroblastoma patients
achieved a mean 4-HPR plasma level of 9.9 mMa tt h e
maximum tolerated dose, 2450 mg·m
-2 per day (Villablanca
et al., 2006). In adults, high dose schedules (1800 mg·m
-2 per
day) have achieved 4-HPR plasma concentrations of 5 to
7 mM with wide interpatient variation (Jasti et al., 2001;
Garcia et al., 2004). Pharmacokinetic data in both children
and adults have suggested that gastrointestinal absorption
was limited at higher doses during phase I studies. New oral
and intravenous formulations of 4-HPR have been developed
to improve bioavailability of the drug (Liu et al., 2007; Maurer
et al., 2007), and are currently being tested in phase I trials in
paediatric and adult malignancies (Mohrbacher et al., 2007;
Marachelian et al., 2009). The interim results from these trials
suggest that increased clinical activity accompanies increased
systemic exposure. Complete responses were observed in 4 of
18 neuroblastoma patients at the highest ﬁve dosing levels
tested with an improved oral powder formulation [4-HPR/
Lym-X-Sorb (LXS)™ oral powder] (Marachelian et al., 2009),
and a 50% response rate (partial + complete) in 10 patients
with relapsed T-cell lymphomas was observed using a
novel intravenous emulsion 4-HPR formulation (MH Kang
et al., unpublished data).
An alternative approach to dose escalation to increase
systemic 4-HPR levels is pharmacological modulation of
4-HPR metabolism. However, before mouse models can be
used for pharmacokinetic studies of 4-HPR pharmacological
modulation, differences in drug metabolism, if any, between
humans and mice need to be deﬁned. In rodents, 4-HPR is
primarily metabolized to N-(4-methoxyphenyl)retinamide
(4-MPR) (Hultin et al., 1986), whereas in humans, 4-HPR
metabolism to 4-MPR and an additional metabolite, 4-oxo-
N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR), have been
reported (Villani et al., 2004). 4-MPR is reported to be the
most abundant metabolite of 4-HPR in both rodent and
human plasma, with 4-oxo-4-HPR being present at lower
concentrations in humans (Villani et al., 2004). 4-MPR is
non-cytotoxic in numerous malignant cell lines, in vitro
(Mehta et al., 1998; Appierto et al., 2001; Villani et al., 2006),
while 4-oxo-4-HPR was two- to fourfold more cytotoxic than
4-HPR in solid tumor cell lines (Villani et al., 2006). While
individual metabolites have been reported both in humans
and rodent models, the metabolic pathways for 4-HPR in
each species still remain poorly delineated.
Several cytochrome P450 (CYP) enzymes, including
CYP3A4, 2C8, 2C9 and 26A1, are reported to metabolize
ATRA into polar derivatives such as 4-oxo-RA (Thatcher,
2005), and these observations have been used to make pre-
dictions concerning metabolic pathways for 4-HPR. Villani
et al. (2004) reported that CYP26A1 catalyzed the formation
of 4-oxo-4-HPR from 4-HPR in a human ovarian carcinoma
cell line, in vitro. Also, in mice pretreated with the CYP
enzyme inducer phenobarbital prior to 4-HPR administra-
tion, hepatic CYP enzyme levels were increased by threefold
and 4-HPR concentrations in plasma and tissues were
decreased by 50% (Hultin et al., 1986). Triazole antifungal
agents are known to inhibit members of the CYP family of
enzymes and to both decrease the levels of polar metabolites
of ATRA and prolong the biological half-life of ATRA (Van
Wauwe et al., 1988; 1990). These observations suggest that
inhibition of the mixed function oxidase system using triaz-
oles could increase systemic 4-HPR levels. A similar approach
employing concurrent ketoconazole, a triazole antifungal
agent, was initially successful in increasing ATRA plasma
levels for 1 or 2 days but failed to prevent the decrease of
ATRA plasma levels at the end of a 2 week treatment course,
possibly because the ATRA-induced CYP enzyme was not
completely inhibited by ketoconazole over the extended
treatment period (Lee et al., 1995). However, unlike ATRA,
where auto-induction of metabolism leads to a signiﬁcant
decrease in half-life and drug exposures during therapy
(Muindi et al., 1994), 4-HPR exposures are relatively constant
during treatment courses and do not show evidence of auto-
induction of metabolism (Formelli and Cleris, 1993). Thus, in
contrast to experiences with ATRA, we hypothesized that the
use of triazoles to inhibit speciﬁc CYP enzymes that metabo-
lize 4-HPR would increase systemic 4-HPR concentrations.
The purpose of this study was therefore to characterize
and compare inter-species differences in the metabolism of
4-HPR in humans and mice, and to determine whether phar-
macological modulation of the metabolism of 4-HPR would
result in higher 4-HPR plasma concentrations in mouse
models. Our pharmacokinetic analyses of plasma from
4-HPR-treated patients and mice identiﬁed six common
metabolites of 4-HPR in humans and mice. We also report in
vitro and in vivo metabolism data suggesting that the inhibi-
tion of CYP3A4 using ketoconazole could result in higher
systemic 4-HPR concentrations clinically.
Methods
Patients
All patients involved in this study gave written informed
consent and the study received Institutional Review Board
approval. Patients whose plasma samples were analyzed for
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Approaches to Neuroblastoma Therapy (NANT) Consortium
(http://www.NANT.org), phase I trial (Study N2004-04) for
the treatment of relapsed and refractory high-risk neuroblas-
toma using 4-HPR delivered in an oral lipid matrix powder
(4-HPR/LXS oral powder, 4-HPR/LXS). Trial design and
interim results have been reported (Marachelian et al., 2009).
Brieﬂy, the trial enrolled 30 evaluable patients to eight dose
levels (range 352–2210 mg·m
-2 per day 4-HPR). 4-HPR/LXS
was administered twice daily for one week every 21 days (one
cycle of treatment). The 4-HPR plasma levels were measured
for three speciﬁc patients treated at the 595 mg·m
-2 per day
dose level. Venous blood samples (5 mL) were taken from the
patients on day 6 of cycle 1 just before one daily dose (i.e.
12 h since the previous dose on day 5) and for the next 8 h at
2 h intervals. Patient blood samples were collected in foil-
wrapped heparinized tubes, centrifuged immediately and
plasma was retained and stored at -80
C until analysis. All
procedures were carried out in amber tubes and/or in the dark
to prevent light exposure.
Animals
All animal care and experimental procedures were approved
by the Institutional Animal Care and Use Committee. Five- to
6 week old non-obese diabetic/severe combined immune
deﬁciency (NOD/SCID) and athymic nude (nu/nu) mice were
obtained from Charles River Laboratories International
(Wilmington, MA, USA). For each experiment, 4-HPR/LXS,
4-HPR/LXS + ketoconazole, or the LXS powder alone (nega-
tive control) was slurried in sterile water and administered via
gavage. Exact dosing and number of doses before pharmaco-
kinetic analysis are given in the legend to Figure 4. After mice
were anesthetized with isoﬂurane, blood samples (approxi-
mately 500 mL) for pharmacokinetic studies were collected by
cardiac puncture and treated as described above for human
samples. Mice were then killed by carbon dioxide narcosis.
High-performance liquid chromatography
(HPLC) and tandem mass spectrometry
(MS/MS) analysis
Levels of 4-HPR, 4-MPR and 4-oxo-4-HPR were quantiﬁed
using an HPLC assay (Vratilova et al., 2004) with the follow-
ing modiﬁcations: HPLC was an Agilent 1200 system (Agilent
Technologies, Palo Alto, CA, USA); column was an Agilent
Zorbax Eclipse reverse-phase C18 150 ¥ 4.6 mm, 5 mm; gradi-
ent elution with 0.01 M ammonium acetate in water and
methanol was used at 1 mL·min
-1; 4-oxo-4-HPR standard was
added; calibration curve concentration range from 0.019 to
40.0 mg·mL
-1; injection volume into the HPLC was 30 mL; and
100 mL of each plasma sample was used for extraction and
analysis. Data were acquired and integrated by ChemStation
3D software (Agilent).
Metabolites were identiﬁed using LC/MS/MS. An Agilent
1200 HPLC was used with an Applied Biosystems 4000
QTRAP MS/MS (Foster City, CA, USA) operated in electro-
spray positive ion mode. For sample preparation, the internal
standard [N-(4-ethoxyphenyl)retinamide (4-EPR)] was added
to 50 mL of plasma and 100 mL of acetonitrile was added,
vortexed and centrifuged at 9300¥ g for 5 min. Supernatants
were then collected and 130 mL of water with formic acid
(0.1%) was added to adjust the acetonitrile concentration to
approximately 30% by volume. Ten mL of supernatant with
adjusted composition was then injected into the LC/MS/MS.
A Waters Corporation reverse-phase Symmetry C18 column
150 ¥ 4.6 mm, 3.5 mm (Milford, MA, USA) was used. The
mobile phase consisted of acetonitrile and water with formic
acid (0.1%) and was delivered via gradient at 1.0 mL·min
-1 for
35 min. The initial mobile phase conditions of 30:70 (v/v,
acetonitrile : aqueous formic acid) were held for 2 min. Con-
centrations were then changed to 95:5 over 23 min and were
held for 3 min. Then at 28 min, concentrations adjusted back
to initial conditions over 2 min and were held for 5 min. The
system was operated in an information-dependent acquisi-
tion mode (threshold: 1000 cps), which was set to include an
MS3 experiment following enhanced product ion spectrum
for the parent ion in the transition. Ion source conditions
were: curtain gas 25; collision gas Low; spray voltage 5000;
temperature 700
C; source gas1 50; source gas2 50. Analyst
(version 1.4.2) and LightSight Metabolite ID software (both
from Applied Biosystems) were used for data acquisition and
processing.
Human (HLMs) and mouse liver
microsomes (MLMs)
4-HPR and 4-MPR metabolism assays were performed using
0.5 mg protein·mL
-1 of pooled HLMs or pooled MLMs, or
human CYP3A4 isoenzyme microsomes (BD Biosciences,
Franklin Lakes, NJ, USA). The NADPH regenerating system
consisted of solutions ‘A’ and ‘B’ (BD Gentest catalog no.
451220 and 451200). Inhibitors of CYP2C8 (gemﬁbrozil)
(Scheen, 2007), CYP2C9 (ﬂuconazole) (Nivoix et al., 2008)
and CYP3A4 (ketoconazole) (Jia and Liu, 2007) were dissolved
in methanol at stock concentrations up to 5 mM. Solutions
‘A’ and ‘B’, liver microsomes and inhibitors were combined in
0.1 M potassium phosphate buffer (pH 7.4), and incubated
for 20 min at 37°C. Substrates were then added and the
mixture was incubated while shaking in a 37°C water bath.
When incubation times were completed, reactions were
immediately terminated by addition of ice-cold acetonitrile
fortiﬁed with internal standard (4-EPR), vortexed for 1 min
and centrifuged at 2917¥ g for 10 min. Supernatants were
collected and analyzed via HPLC as described earlier.
Cell lines
Human acute lymphoblastic leukemia (ALL) cell lines COG-
LL-317, -332 and -329 (all T-cell ALL); COG-LL-319 and -355
(both Pre-B ALL); and COG-LL-356 (Pro-B ALL); and neuro-
blastoma lines CHLA-90 and -136 were obtained from the
Children’s Oncology Group Cell Culture Repository (http://
www.COGcell.org). Cells were cultured in Iscove’s Modiﬁed
Dulbecco’s Medium (Cambrex, Walkersville, MD, USA)
supplemented with 3 mM L-glutamine, 5 mg·mL
-1 insulin and
20% heat-inactivated fetal bovine serum (FBS). The human
Pre-B ALL cell line NALM-6 (from Deutsche Sammlung
von Mikroorganismen und Zellkulturen, Braunschweig,
Germany); and human cell lines CCRF-CEM, MOLT-3 and
MOLT-4 (all T-cell ALL), RS4;11 (Pre-B ALL), GA-10 (B-cell
Burkitt lymphoma), HuT-78 (cutaneous T-cell lymphoma)
and Toledo (B-cell non-Hodgkin lymphoma), all from
American Type Culture Collection, Manassas, VA, USA, were
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supplemented with 10% heat-inactivated FBS. All lines tested
mycoplasma-free. Lymphoid cell lines were maintained at
37
C in humidiﬁed incubators containing 5% O2,5 %C O 2
and 90% N2, and neuroblastoma lines were maintained at
37
C in humidiﬁed incubators containing 95% room air and
5% CO2. Cell line identities were conﬁrmed after each expan-
sion but prior to freezing by short tandem repeat (STR) geno-
typing using Ampf/STRTM Identiﬁer TM kit (Applied
Biosystems) (Masters et al., 2001) and compared with the
Children’s Oncology Group STR database (http://www.
COGcell.org). STR proﬁles were performed in all cell lines for
cell line identiﬁcation one month before the experiments.
Real-time reverse transcription-polymerase
chain reaction (RT-PCR)
RT-PCR was performed using an Applied Biosystems Prism
7900HT system to quantify basal gene expression of CYP26A1
in each of fourteen malignant lymphoid cell lines and two
neuroblastoma cell lines. The reagents, assay conditions and
data normalization methods were as previously described
(Kang et al., 2008). Primers and probes for CYP26A1 (TaqMan
Gene Expression Assay proprietary sequences, P/N 4331102;
Applied Biosystems) were added according to the manufac-
turer’s instructions. Total RNA added per well was 300 ng for
all cell lines except CCRF-CEM, for which 150 ng was added
because of its apparently high level of CYP26A1 mRNA.
Statistical analysis
Statistical evaluation was performed using Student’s t-test.
P-values were two sided and tests were considered signiﬁcant
at P < 0.05. All in vitro experiments were performed in tripli-
cate and were consistently repeatable; for simplicity, one rep-
resentative experiment for each condition is shown.
Materials
4-HPR, 4-MPR and 4-EPR were supplied by the Developmen-
tal Therapeutics Program of the National Cancer Institute
(NCI, Bethesda, MD, USA). 4-oxo-4-HPR was synthesized as
previously described (Villani et al., 2004). 4-HPR/LXS™ oral
powder and LXS™ oral powder was from Avanti Polar Lipids,
Inc, Alabaster, AL, USA, manufactured under agreement with
BioMolecular Products, Newburyport, MA, USA, and the for-
mulation was supported by NCI Rapid Access to Intervention
Development Program. Ketoconazole, gemﬁbrozil, and ﬂu-
conazole were from Sigma-Aldrich (St Louis, MO, USA). Potas-
sium phosphate monobasic, acetonitrile, methanol and
formic acid were from Fisher Scientiﬁc (Pittsburgh, PA, USA).
Results
Identiﬁcation of 4-HPR metabolites in the
plasma of 4-HPR-treated patients and mice
To identify metabolites of 4-HPR, we used LC/MS/MS to
analyze plasma samples from 4-HPR-treated patients and
mice. HPLC chromatograms of patient plasma and mouse
plasma are shown in Figure 1A left and right panels respec-
tively. 4-HPR eluted at approximately 25.0 min and the
detected metabolites had retention times ranging from 7.6 to
27.5 min. In both species, seven major peaks (peak area ratio
> 0.04 relative to the parent drug in humans and >0.12
relative to the parent drug in mice) representing different
4-HPR metabolites were detected, M1-M7 in mouse plasma
and H2-H8 in human plasma. Six of these seven peaks,
M2–M7 in mouse plasma and H2–H7 in human plasma, were
eluted at similar retention times (i.e. were metabolites,
common to both species).
The results of MS/MS analysis of patient and mouse
plasma are shown in Figure 1B. Two of the metabolites in
patients (H6 and H7) and two in mice (M6 and M7) were
detected using a positive precursor ion scan at m/z 283,
which is the fragment occurring after loss of the amino-
phenyl-hydroxy group. The structure of H7 and M7 identiﬁed
the two metabolites as 4-MPR, while H6 and M6 showed an
[M + H]
+ ion at m/z 568 and fragmentation spectra corre-
sponding to the direct addition of glucuronide to 4-HPR.
Metabolites H2–H4, H8 and M2–M4 were detected by a
neutral loss scan of 109. The fragmentation spectra identiﬁed
metabolites H4 and M4 as 4-oxo-4-HPR, and the spectra of
H2, M2 and H8 each corresponded to a monohydroxy-4-oxo-
4-HPR. The exact location of the hydroxyl group on the
4-oxo-substituted b-ionone ring could not be determined for
H2, M2 or H8 as hydroxylation could occur at any of the C-2,
C-3 or C-18 positions. The metabolites H3 and M3 were
identiﬁed as dehydrogenated 4-HPR. Finally, metabolites M1,
H5 and M5 were detected by a precursor ion scan at m/z 313,
which is the fragment occurring after loss of the amino-
phenyl-hydroxy group from monohydroxy-4-oxo-4-HPR.
Fragmentation spectra suggested that M1 was a glucu-
ronidated metabolite and that H5 and M5 were both sulfated
metabolites.
In vitro metabolism of 4-HPR in liver
microsomes and malignant mammalian cells
Identiﬁcation of 4-oxo-4-HPR in the plasma of mice
prompted us to measure and compare the Michaelis–Menten
kinetic constants for the oxidation of 4-HPR to 4-oxo-4-HPR
in pooled HLMs and pooled MLM using HPLC (Figure 2A and
B). The Vmax was more than threefold greater for HLM com-
pared with MLM (1.50 vs. 0.42 nmol·h
-1 per mg protein), but
the Km values were equivalent (23.9 vs. 25.8 mM), showing
that 4-oxo-4-HPR generation in mice is slower but the total
amount formed in mice is similar to humans. We also inves-
tigated whether 4-MPR, the major metabolite of 4-HPR, could
be demethylated to form 4-HPR or 4-oxo-4-HPR in HLM
(Figure 2C, D). Although the Vmax and Km values were low for
4-MPR, both 4-HPR and 4-oxo-4-HPR were detected as
metabolites of 4-MPR in HLM. Neither 4-HPR nor 4-oxo-4-
HPR were produced from 4-MPR at measurable concentra-
tions in MLM (data not shown).
As the CYP enzymes 3A4, 2C8, 2C9 and 26A1 have been
shown to metabolize ATRA into polar metabolites including
4-oxo-ATRA (Thatcher, 2005), we investigated whether these
enzymes contributed to the formation of 4-oxo-4-HPR from
4-HPR in humans and mice. Three of these enzymes
(CYP2C8, 2C9 and 3A4) are inhibited by agents that are
readily available and well tolerated in humans, making
the inhibitors of the enzymes clinically applicable for
co-administration with 4-HPR. To identify the CYP enzymes
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Identiﬁcation of N-(4-hydroxyphenyl)retinamide (4-HPR) metabolites in plasma of 4-HPR-treated patients and mice. (A) HPLC chromatograms
showing metabolite peaks in humans (H2–H8, left) and mice (M1–M7, right). Pre-4-HPR (blue), after 4-HPR (red). (B) Structural identiﬁcation of
H2–H8 and M1–M7 via tandem mass spectrometry (MS/MS). Dehydration that occurred during fragmentation of M1, H2/M2, H5/M5 and H8
is likely to involve the hydroxyl (-OH) group highlighted with red box.
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and MLM, inhibitors to CYP2C8 (gemﬁbrozil), 2C9 (ﬂucona-
zole) and 3A4 (ketoconazole) were added to MLM and HLM
in combination with 4-HPR and the amount of 4-oxo-4-HPR
formation was measured via HPLC (Figure 3). A 4-HPR con-
centration of 25 mM, an approximated Km from both MLM
and HLM experiments, was used for the formation of 4-oxo-
4-HPR from 4-HPR. In MLM (Figure 3A), the addition of ﬂu-
conazole reduced 4-oxo-4-HPR formation by 40.9%  4.1 at
10 mM from 4-HPR alone (P < 0.01) and ketoconazole reduced
4-oxo-4-HPR formation by 96.5%  3.1 at 10 mM from 4-HPR
alone (P < 0.001). In HLM (Figure 3B), only ketoconazole
reduced 4-oxo-4-HPR formation (33.7%  8.8 from 4-HPR
alone at 10 mM, P < 0.01). To conﬁrm that human CYP3A4
catalyzed the formation of 4-oxo-4-HPR from 4-HPR, we incu-
bated 4-HPR (at 10 mM anticipating that the CYP3A4 isoen-
zyme activity would be higher than in pooled HLMs) in
human CYP3A4 isoenzyme microsomes with the NADPH
generating system and analyzed amounts of 4-HPR and
4-oxo-4-HPR via HPLC. We found that 4-oxo-4-HPR concen-
trations in the CYP3A4 microsomes increased in a time-
dependent manner (Figure 3C).
As ketoconazole at 10 mM partially inhibited 4-oxo-4-HPR
production in HLM, and ketoconazole is reported to be spe-
ciﬁc for CYP3A4 at concentrations up to 1 mM but will inhibit
other CYP isoforms at higher concentrations (Jia and Liu,
2007), we considered the possibility that other CYP enzymes
might be contributing to 4-oxo-4-HPR formation in cancer
patients. Expression of CYP26A1 was reported to be induced
after exposure to 4-HPR in a human ovarian cancer cell line,
and 4-oxo-4-HPR formation from 4-HPR was measured after
overexpression of CYP26A1 (Villani et al., 2004), so we inves-
tigated whether CYP26A1 formed 4-oxo-4-HPR from 4-HPR
in human malignant lymphoid cell lines and neuroblastoma
cell lines. We ﬁrst measured basal CYP26A1 mRNA levels via
RT-PCR in fourteen malignant lymphoid cell lines grown at
physiological bone marrow level hypoxia (5% O2) and two
neuroblastoma cell lines grown at ‘normoxic’ tissue culture
conditions (20% O2). mRNA for CYP26A1 was quantiﬁed in
all cell lines and the levels were comparable between the
malignant lymphoid cells (range 0.03–1.27) and the neuro-
blastoma cells (CHLA-90: 0.108 and CHLA-136: 0.076).
However, when we used HPLC to examine cellular extracts
from ﬁve of the malignant lymphoid cell lines (CCRF-CEM,
Figure 2
In vitro metabolism of N-(4-hydroxyphenyl)retinamide (4-HPR) and N-(4-methoxyphenyl)retinamide (4-MPR) in pooled human (HLM) and mouse
liver microsomes (MLM). (A) Rate of 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) formation from 4-HPR in HLM and (B) in MLM. (C) Rate
of demethylation of 4-MPR to the parent drug in HLM. (D) Rate of 4-oxo-4-HPR formation from 4-MPR in HLM. (A–D) Substrates at indicated
concentrations were incubated in HLM or MLM for 60 min. Points in each graph are the mean and error bars are standard deviation from
experiments performed in triplicate. Amounts measured by HPLC were normalized to the amount of HLM or MLM protein. In each graph, the
Km (mM) and Vmax (nmol·h-1 mg protein-1) are the mean  SD.
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blastoma cell lines after treatment with 2–10 mM 4-HPR for 12
and 24 h. 4-oxo-4-HPR was not formed at measurable con-
centrations (data not shown).
Co-administration of ketoconazole with
4-HPR increased systemic 4-HPR levels
in vivo
To examine whether the modulation of 4-HPR metabolism
would alter systemic 4-HPR levels in vivo, we administered
4-HPR with or without ketoconazole at human treatment-
equivalent dosing to nu/nu and NOD/SCID mice. In nu/nu
mice (Figure 4A) the addition of 75 mg·kg
-1 of ketoconazole
(representing a human equivalent dose of 6 mg·kg
-1, which is
within the therapeutic dosing range for children and adults)
increased 4-HPR plasma levels from 14.5 mM  4.7 to 31.5 mM
 1.9 (a 2.2-fold increase over control, P < 0.01), and in
NOD/SCID mice (Figure 4B) ketoconazole signiﬁcantly
increased 4-HPR plasma levels at all doses (at 18.75 mg·kg
-1,
an increase from 8.5 mM  4.4 to 28.9 mM  3.1, a 3.4-fold
increase over control, P < 0.01). In a separate experiment, the
addition of 25 mg·kg
-1 ketoconazole to 4-HPR in NOD/SCID
mice (Figure 4C) increased 4-HPR plasma levels from 15.6 mM
 4.5 to 31.6 mM  2.7 (a twofold increase over control, P <
0.02) and also increased levels of 4-oxo-4-HPR from 3.6 mM 
0.4 to 7.2 mM  0.8 (a twofold increase over control, P < 0.01).
Comparison of levels of 4-HPR and Its
metabolites in the plasma of 4-HPR-treated
patients and mice
Using HPLC, we analyzed the concentrations of 4-HPR,
4-MPR and 4-oxo-4-HPR in the plasma of three patients
enrolled in a phase I clinical trial of 4-HPR/LXS (Table 1).
Blood samples were taken from three patients treated at the
4-HPR dose-level of 595 mg·m
-2 per day, just before the ﬁrst
dose of the day and then at 2 h intervals up to 8 h after
Figure 3
CYP enzymes catalyzing the formation of 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) from N-(4-hydroxyphenyl)retinamide (4-HPR). (A,
B) Analysis of the effects of CYP enzyme inhibitors on 4-oxo-4-HPR formation from 4-HPR in (A) pooled mouse (MLM) and (B) pooled human liver
microsomes (HLM). 4-HPR (25 mM) was incubated with or without the indicated concentration of CYP enzyme inhibitor in MLM or HLM for
60 min before analysis via HPLC. (C) Formation of 4-oxo-4-HPR from 4-HPR via human CYP3A4 isoenzyme. In human CYP3A4 isoenzyme
microsomes, 4-HPR (10 mM) was incubated for the times indicated. Amounts of 4-HPR and 4-oxo-4-HPR measured by HPLC were normalized to
the amount of CYP3A4 protein. 4-HPR (10 mM) was used as a positive control in HLM to conﬁrm the generation of 4-oxo-4-HPR. (A–C) The
points/columns are the mean and error/vertical bars are standard deviation from experiments performed in triplicate. **P < 0.01, ***P < 0.001.
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sample taken 4 h after treatment (the middle of the 8-h sam-
pling period), 4-HPR, 4-MPR and 4-oxo-4-HPR levels were
12.82 mM  8.08, 5.72 mM  4.21 and 0.86 mM  0.66 respec-
tively. By comparison, in the plasma of NOD/SCID mice that
were administered 4-HPR/LXS at a 4-HPR dose approximately
equivalent to the dose administered in the patients (patients:
595 mg·m
-2 per day and mice: 180 mg·kg
-1 per day) (Reagan-
Shaw et al., 2008), average levels of 4-HPR, 4-MPR and 4-oxo-
4-HPR were 15.6 mM  4.5, 1.6 mM  0.2 and 3.6 mM  0.4
respectively (control mice in Figure 4C).
Discussions and conclusions
Low plasma drug levels and tumor response rates in clinical
trials employing an oral corn-oil slurry based 4-HPR capsule
have led investigators to suggest that higher systemic 4-HPR
exposures may be required to improve clinical outcomes
(Cheng et al., 2001; Puduvalli et al., 2004; Vaishampayan
et al., 2005; Reynolds et al., 2007; William et al., 2009). As a
result, new formulations that increase 4-HPR bioavailability
have been developed (Liu et al., 2007; Maurer et al., 2007) and
are currently being tested in phase I trials (Mohrbacher et al.,
2007; Marachelian et al., 2009). However, the possibility that
systemic 4-HPR exposures could be further improved by
modulating 4-HPR metabolism in conjunction with oral
delivery has not been investigated. Based on reports suggest-
ing that both ATRA and 4-HPR metabolism occurs via CYP
enzymes (Hultin et al., 1986; Van Wauwe et al., 1988; 1990;
1994; Thatcher, 2005; Villani et al., 2004), we hypothesized
that pharmacological inhibition of CYP enzymes that
metabolize 4-HPR using clinically-available agents might
increase systemic 4-HPR concentrations.
Figure 4
Co-administration of ketoconazole increased systemic N-(4-hydroxyphenyl)retinamide (4-HPR) levels in mice in vivo. (A) 4-HPR and N-(4-
methoxyphenyl)retinamide (4-MPR) levels in plasma of nu/nu mice given 4-HPR with increasing doses of ketoconazole. The mice were killed 4 h
after the ninth dose. (B) 4-HPR and 4-MPR levels in plasma of non-obese diabetic/severe combined immune deﬁciency (NOD/SCID) mice given
4-HPR with increasing doses of ketoconazole. Assay times were the same as described for Figure 4A. (C) 4-HPR, 4-MPR and 4-oxo-N-(4-
hydroxyphenyl)retinamide (4-oxo-4-HPR) levels in plasma of NOD/SCID mice given 4-HPR alone or with ketoconazole (25 mg·kg
-1). Mice in both
groups were killed 4 h after the ﬁfth dose. In panels A–C, all mice received 4-HPR (180 mg·kg
-1 per day) gavaged in two divided doses; control
mice for all experiments received 4-HPR without ketoconazole. Cohorts of three mice were used for each condition and columns are the mean
and error/vertical bars are standard deviation from experiments performed in triplicate. *P < 0.02, **P < 0.01.
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how 4-HPR metabolism in humans compared with in vivo
murine models as the metabolic pathways for 4-HPR are
poorly deﬁned in both species. In this study, we determined
both similarities and differences in 4-HPR metabolism
between humans and mice. Using human and MLMs we
demonstrated that 4-oxo-4-HPR is formed from 4-HPR by
CYP3A4 in mice and, in part, by CYP3A4 in human cells in
vitro; we further demonstrated that the co-administration of
the CYP3A4-inhibitor, ketoconazole, with 4-HPR in vivo
increased 4-HPR plasma concentrations in mice.
The demonstrated similarities and differences in 4-HPR
metabolism between humans and mice suggests that mouse
models may be useful in vivo models of 4-HPR pharmacoki-
netics and studies of pharmacological manipulation in
humans within certain limitations. Speciﬁcally, differences in
the kinetic constants for oxidation of 4-HPR to 4-oxo-4-HPR
in HLM and MLM were observed, suggesting that mice
proportionately oxidize a greater portion of 4-HPR to
4-oxo-4-HPR than do humans. Also, the observation that
ketoconazole inhibited 4-HPR conversion to 4-oxo-4-HPR at
lower concentrations in MLM than in HLM, suggesting that
mice may rely more heavily on CYP3A4 for 4-oxo-4-HPR
formation than humans. In terms of similarities, the low
kinetic constants for conversion of 4-MPR to 4-HPR or 4-oxo-
4-HPR in HLM (Figure 2C and D) and the absence of conver-
sion in MLM suggest that neither conversion occurs at high
rates or amounts in humans or mice. Thus, while 4-MPR is
reported to accumulate to high levels in plasma and tissues
and to have a longer half-life than 4-HPR (Formelli and Cleris,
1993; Sabichi et al., 2003; Formelli et al., 2008), it is unlikely
that back conversion (i.e. ‘recycling’) of the 4-MPR pool in
plasma signiﬁcantly contributes to systemic 4-HPR levels or
tumor cell 4-HPR exposure. A proposed biotransformation
pathway of 4-HPR is shown in Figure 5 based on the data
from human and mouse plasma analyses and the in vitro
enzyme kinetic studies.
Our in vitro studies demonstrated that inhibitors of both
CYP2C9 (ﬂuconazole) and CYP3A4 (ketoconazole) signiﬁ-
cantly reduced 4-oxo-4-HPR formation in MLM, but that in
HLM ketoconazole only partially inhibited 4-oxo-4-HPR for-
mation. We then demonstrated that the co-administration of
ketoconazole at human treatment-equivalent doses with
4-HPR in vivo increased 4-HPR plasma levels by at least
twofold in two strains of mice, with NOD/SCID mice possibly
being more sensitive to ketoconazole effects than nu/nu
mice. These in vitro and in vivo data are compatible with
results from a study by Illingworth et al. (2011), and support
the role of CYP3A4 in the oxidation of 4-HPR. However, given
that relatively high concentrations of ketoconazole were
used to inhibit 4-oxo-4-HPR formation in HLM both in our
study (10 mM) and in the study by Illingworth et al. (2011)
(100 mM), it is likely that other CYP enzymes in addition to
3A4 contribute to 4-oxo-4-HPR formation in humans.
Based on the fact that we observed greater inhibition of
4-oxo-4-HPR formation by ketoconazole in MLM versus HLM
(96.5% vs. 33.7% at 10 mM, see Figure 3A and B), the present
results suggest that experiments in mice may overestimate
the increase in 4-HPR plasma levels to be expected in humans
when using concurrent administration of ketoconazole and
4-HPR, if such increases are based solely on the inhibition of
metabolism of 4-HPR to 4-oxo-4-HPR. However, ketoconazole
may inhibit other CYP enzyme isoforms in addition to 3A4 at
concentrations above 1 mM (Jia and Liu, 2007). Thus keto-
conazole co-treatment has the potential to decrease the con-
version of 4-HPR to metabolites other than 4-oxo-4-HPR and
could result in higher 4-HPR plasma levels in patients than
would be suggested by analysis of 4-oxo-4-HPR formation
alone in HLM. Also, importantly, although 4-oxo-4-HPR may
obtain lower steady-state plasma levels than other 4-HPR
metabolites in humans, the speciﬁc mass per time (ﬂux) of
4-HPR through 4-oxo-4-HPR metabolism in humans is not
known and, if great enough, could represent a useful target
for pharmacological intervention by ketoconazole or other
agents on this basis.
Based on microsomal results, in addition to increasing
4-HPR plasma levels we expected that co-administration of
ketoconazole to mice would also result in a concomitant rise
in 4-MPR plasma levels (as oxidation of 4-HPR was inhibited,
more 4-HPR was available to the other metabolic pathways).
However, in addition to a slight increase in 4-MPR levels,
surprisingly, ketoconazole increased 4-oxo-4-HPR plasma
Table 1
N-(4-hydroxyphenyl)retinamide (4-HPR), N-(4-methoxyphenyl)retinamide (4-MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR)
levels in plasma of neuroblastoma patients
Hours after treatment
(n = 3)
Mean  standard deviation (mM)
4-HPR 4-MPR 4-oxo-4-HPRa
0 7.04  4.75 4.03  2.98 0.91b
2 9.69  7.30 4.91  3.69 1.27
b
4 12.82  8.08 5.72  4.21 0.86  0.66c
6 13.11  8.50 6.61  5.75 0.43b
8 8.55  6.42 4.69  3.92 1.00  0.72d
Blood was taken from three patients treated at the 595 mg·m-2 per day dose level. All blood samples were collected on day 6 of cycle 1, just
before and after the ﬁrst dose of the day, and plasma was prepared as described. Doses of 4-HPR were given twice a day, 12 h apart and the
zero time value represents blood taken just before the ﬁrst dose of day 6, that is, 12 h after the last dose on day 5.
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Considering that CYP3A4 may also mediate the formation of
dehydrogenated 4-HPR and hydroxy-4-oxo-4-HPR, and that
the metabolism of both ATRA and 4-oxo-4-ATRA has been
reported to be inhibited by imidazole-containing P450
inhibitors such as ketoconazole and liarazole (Hultin et al.,
1986; Van Wauwe et al., 1990; Van et al., 1994; Chithalen
et al., 2002), it is possible that other CYP enzymes, including
CYP26A1 whose expression has been shown to be inducible
by ATRA and 4-HPR (Sonneveld et al., 1998; Ozpolat et al.,
2002; 2004; Villani et al., 2004), may also contribute to the in
vivo formation of 4-oxo-4-HPR. Another possible explanation
of having slightly increased 4-oxo-4-HPR in mice is that keto-
conazole inhibited further degradation of 4-oxo-4-HPR into
hydroxyl-4-oxo-4-HPR (see Figure 5), and that the increases
in 4-HPR concentration resulted from the inhibition of dehy-
drogenated 4-HPR formation which generated more 4-oxo-4-
HPR in sequence.
As the metabolite 4-oxo-4-HPR is reported to exhibit more
potent anti-tumor activity than 4-HPR and has also been
shown to act synergistically with the parent compound
(Villani et al., 2006), one may question whether the inhibi-
tion of 4-oxo-4-HPR formation might compromise the efﬁ-
cacy of 4-HPR. While the anti-tumor activity of 4-HPR has
been demonstrated both with in vivo models and clinically
(Maurer et al., 2007; Mohrbacher et al., 2007; Reynolds et al.,
2007; Marachelian et al., 2009), only in vitro studies with
4-oxo-4-HPR are reported and it has not been investigated
whether this translates to an anti-tumor role in vivo. Further,
it is hypothesized that sufﬁciently increasing 4-HPR levels
will result in increased anti-tumor activity that will more
than adequately compensate for a possible partial decrease in
4-oxo-4-HPR levels. Indeed, in our in vivo mouse experiments,
ketoconazole did not appreciably reduce 4-oxo-4-HPR levels
in the plasma while 4-HPR concentrations approximately
doubled, suggesting the further metabolism of 4-oxo-4-HPR
to hydroxy-4-oxo-4-HPR might have been inhibited by keto-
conazole as previously discussed.
Unfortunately, due to the lack of a sufﬁciently speciﬁc
inhibitor of CYP26A1 and CYP26A1 isoenzymes, we could
Figure 5
Proposed phase I and II biotransformation pathway for N-(4-hydroxyphenyl)retinamide (4-HPR). Potential pathways for the interconversion of one
metabolite into another, that is, the conversion of N-(4-methoxyphenyl)retinamide (4-MPR) to 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-
HPR), have been omitted due to the very low/no conversion kinetic parameters observed in HLM and MLM.
BJP
JP Cooper et al.
1272 British Journal of Pharmacology (2011) 163 1263–1275not address whether the formation of 4-oxo-4-HPR from
4-HPR is also catalyzed by CYP26A1 using liver microsome
analyses or in vivo mouse studies. However, we assayed 4-oxo-
4-HPR formation in seven human malignant lymphoid and
neuroblastoma cell lines expressing CYP26A1 that were
exposed to 4-HPR and 4-oxo-4-HPR was not measurable in
any of the cell lines tested. These results in lymphoid cancer
and neuroblastoma cell lines with basal levels of CYP26A1
expression differ from those reported by Villani et al., who
employed forced overexpression of CYP26A1 in an ovarian
cancer cell line (Villani et al., 2004), and may have therapeu-
tic implications. Our results suggest that the limited amount
of internal tumor 4-oxo-4-HPR formed by CYP26A1 and/or
other enzymes in human malignant lymphoid and neuro-
blastoma cell types in vivo may not be responsible for the
observed clinical activity of 4-HPR, although our studies did
not address the possible effects of peripheral tissue metabo-
lism of 4-HPR to 4-oxo-4-HPR and the effects of those 4-oxo-
4-HPR sources on tumor responses. Conceivably, 4-HPR-
resistant malignant cells may have increased expression of
CYP26A1 and be capable of generating clinically signiﬁcant
local amounts of 4-oxo-4-HPR. Thus, it is difﬁcult to directly
predict the clinical impact, if any, that 4-HPR-resistant,
4-oxo-4-HPR-producing malignant cells may have on 4-HPR
global pharmacokinetics as the relative contributions to
4-HPR metabolism of various tissues (liver, intestines,
kidneys, etc.) and of varying tumor cell burdens remain to be
determined.
Finally, we compared the levels of 4-HPR, 4-MPR and
4-oxo-4-HPR in the plasma of 4-HPR-treated patients and
mice treated with human-equivalent doses of 4-HPR (Reagan-
Shaw et al., 2008). When compared with 4-HPR and metabo-
lite plasma concentrations observed in a phase I trial
employing oral capsule 4-HPR in paediatric neuroblastoma
patients at similar doses, the 4-HPR and 4-MPR levels mea-
sured in patients treated with 4-HPR/LXS oral powder
appeared to be higher but the 4-oxo-4-HPR levels were
approximately equivalent. Further, while the 4-HPR plasma
concentrations measured in the present investigation were
not appreciably different between patients and mice dosed on
an equivalent basis, NOD/SCID mice appeared to convert
more 4-HPR to 4-oxo-4-HPR while humans preferentially
metabolized 4-HPR to 4-MPR (Table 1 and control mice in
Figure 4C). This observed result seems to be at odds with the
kinetic constants estimated by our in vitro studies, which
suggested that humans and mice would form similar
amounts of 4-oxo-4-HPR. Kinetic data, however, cannot be
interpreted in isolation as other reactions may inﬂuence drug
metabolism. It is also worth noting that our clinical and in
vivo data are currently limited by small numbers of patients,
a restricted patient age range (<26 years old), and by the
number of strains of mice analyzed for 4-oxo-4-HPR. Further,
the potentially greater responsiveness of NOD/SCID mice
with respect to the extent to which ketoconazole increased
4-HPR levels (Figure 4A and B) suggests that not all mouse
strains metabolize 4-HPR equivalently.
In summary, our evidence suggests that, overall, humans
and mice metabolize 4-HPR to a common set of metabolites
and the demonstration that the co-administration of keto-
conazole increased 4-HPR plasma levels in mice strongly
support the possibility that a similar effect may be observed
in patients. The addition of a study arm to test the effect of
the co-administration of ketoconazole on 4-HPR plasma
levels and systemic toxicity in an on-going phase I trial of
4-HPR/LXS oral powder in paediatric neuroblastoma in the
New Approaches to Neuroblastoma Therapy (NANT) Consor-
tium (http://www.NANT.org) is in progress. Considering that
relatively low human-equivalent doses of ketoconazole were
sufﬁcient to increase 4-HPR systemic exposure in mice, the
combination of 4-HPR and ketoconazole is expected to be
well tolerated in patients.
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